Chronic Immune Checkpoint Inhibitor Pneumonitis in Patients with NSCLC

2021 Year in Review: Non–Small-Cell Lung Cancer —December 29, 2021

Categories:

Lung Cancer

Immune checkpoint inhibitor (ICI) pneumonitis is a lung immune-related adverse event that frequently necessitates ICI withdrawal. Whereas some cases of pneumonitis respond to corticosteroid therapy within the recommended 4 to 6 weeks, others do not improve or have several causes, necessitating prolonged or recurrent courses of steroids.1

Chronic rates of pneumonitis were measured in a study of 869 patients with non–small-cell lung cancer (NSCLC) who were started on ICIs at one institution between 2011 and 2019. Any pneumonitis requiring a total of ≥12 weeks of steroids, given either continuously or during numerous treatment courses, was defined as chronic pneumonitis.1 Of the 869 patients studied, 5.1% had ICI pneumonitis, and 50% of these patients had chronic pneumonitis. The median number of weeks on corticosteroid therapy for patients with chronic pneumonitis was 25.9 weeks (range, 12.4-114.4 weeks). Additional immunosuppressive medications, such as mycophenolate or infliximab (Remicade), were required in 4 patients.1

Other studies have shown that ICI pneumonitis is more common and severe in a real-world cancer cohort. Confounding diagnoses are frequently encountered when patients receiving ICI treatment experience worsening dyspnea or respiratory failure.2 Chronic pulmonary disorders such as interstitial lung disease, chronic obstructive pulmonary disease, and fibrosis on chest computed tomography imaging appear to enhance the risk for ICI pneumonitis and may be important contributors to the higher ICI pneumonitis burden in patients with lung cancer.2

In the study of 869 patients with NSCLC receiving ICI therapy, half of the patients who were identified with pneumonitis went on to develop chronic pneumonitis, which required ≥12 weeks of glucocorticoid medication. Some patients required a longer steroid course, whereas others first recovered and subsequently reappeared, even after the ICI was stopped. In the treatment of patients with ICI pneumonitis, it is critical to recognize chronic pneumonitis as a unique and prevalent clinical entity.1

Immune checkpoint pneumonitis that is steroid resistant is uncommon, yet it is linked with considerable morbidity and mortality.3 Additional immunomodulators can result in long-term improvement in more than one-third of patients. In the future, a better knowledge of the underlying biology of immune-related pneumonitis will be essential for developing more precise and effective treatment techniques.3 These findings call for more prospective trials and imply that patients with chronic lung illness who are receiving ICI therapy should undergo extra pretreatment or posttreatment testing.2

References

  1. Stuart J, Ricciuti B, Machado Alessi JV, et al. Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):Abstract 9103.
  2. Atchley WT, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest. 2021;160:731-742.
  3. Beattie J, Rizvi H, Fuentes P, et al. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021;9:e001884.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country